by It helps in studying ion channel behavior and discover drugs targeting specific ion channels. The automated patch clamp system finds applications in drug discovery, drug screening, toxicology testing and translational research. The technology enables precise electrical recordings from live cells at a much faster rate.
The Global automated patch clamp system market is estimated to be valued at US$ 579.83 Mn in 2024 and is expected to exhibit a CAGR of 6.0% over the forecast period from 2024 to 2030.
Key Takeaways
Key players operating in the automated patch clamp system are GE Healthcare, Siemens Healthineers, Philips Healthcare, Toshiba Medical Systems Corporation, Hitachi Healthcare, Canon Medical Systems Corporation, Mindray Medical International Limited, Esaote SpA, NeuroLogica Corporation, NeuroVive Pharmaceutical AG, Brainlab AG, Akili Interactive Labs Inc., Brainomix Ltd., Imaging Science International, Mevis Medical Solutions, NeuroVista, Neusoft Medical Systems, Positron Corporation, Shimadzu Corporation, Trifoil Imaging. The growing demand for ion channel screening in drug discovery and rising investments in pharmaceutical R&D are fueling the demand for automated patch clamp systems. Advances in microfluidic chip technologies and sensor miniaturization have enabled higher throughput screening and miniaturization of automated patch clamp systems.
Market Trends
Increasing adoption of multi-well plate assays: Key players are offering automated patch clamp systems integrated with multi-well plates to achieve ultra-high throughput screening of over 1000 compounds per day. This is helping research laboratories screen large compound libraries within a short duration.
Growing popularity of cell-based assays: Cell-based assays using living cells are gaining traction over conventional molecular-based assays as they better mimic in vivo conditions. Automated patch clamp systems enable reliable, reproducible and standardized cell-based ion channel screening and receptor trafficking assays.
Market Opportunities
Drug repurposing for COVID-19: Researchers are investigating if existing FDA approved drugs can be repurposed for treating COVID-19 using automated patch clamp systems to screen drug candidates that target viral ion channels. This presents an opportunity for growth of these systems.
Growing drug discovery outsourcing: Pharma companies are increasingly outsourcing primary drug screening to contract research organizations (CROs) equipped with automated patch clamp systems. This is expected to drive the demand for high throughput screening systems in CROs.
Impact of COVID-19 on Automated Patch Clamp System Market Growth
The COVID-19 pandemic has significantly impacted the growth of the Automated Patch Clamp System Market Size. During the initial lockdown phases declared by governments across major countries, most research laboratories conducting cell-based research were shut down to curb the spread of the virus. This led to a decline in demand for automated patch clamp systems in 2020.
However, COVID-19 also accelerated the need for drugs and vaccines against the novel coronavirus. This boosted research activities focused on virus-host interaction studies using cell-based assays. As a result, the demand for automated patch clamp systems picked up in 2021 as more research laboratories resumed operations with necessary safety protocols. Additionally, the pandemic highlighted the importance of developing novel drugs at a rapid pace to effectively tackle public health emergencies. This has increased investments in cell-based research capabilities going forward.
While supply chain disruptions caused minor delays in production and delivery of automated patch clamp systems during the peak pandemic phase, major players were able to overcome these issues by the end of 2020. The growing need for COVID-19 related research and a focus on pandemic preparedness are projected to drive higher adoption of automated patch clamp systems in the forecast period. Advancements that enhance throughput and optimization of virus-host interaction studies will be important for leveraging cell-based platforms against future health crises.
Geographical Regions with Higher Concentration of Automated Patch Clamp System Market
North America dominated the global automated patch clamp system market in terms of value in 2024. This can be attributed to strong government support for life science research and presence of leading pharmaceutical and biotechnology companies conducting drug discovery and development activities in the region. Several top national laboratories and academic research institutes in the US and Canada are well-equipped with automated patch clamp systems to study ion channel physiology and screening.
Asia Pacific is the fastest growing regional market for automated patch clamp systems. Factors such as increasing healthcare expenditure, expanding biomedical industry, and focus on developing local manufacturing capabilities are driving higher adoption of advanced research tools like automated patch clamp systems in countries like China, India, South Korea and Japan. The region offers lucrative growth opportunities for market players as life science research investments in Asia Pacific continue gaining momentum.
Fastest Growing Region for Automated Patch Clamp System Market
Asia Pacific market is projected to expand at the highest CAGR during the forecast period. This can be attributed to rising R&D spending on drug development and cell-based research by pharmaceutical and biotechnology companies based in emerging Asian economies. Continuous policy support from governments to build local life science manufacturing and strengthen clinical research infrastructure is positively impacting the Asia Pacific automated patch clamp system market. Growing biomedical industry in China and India, coupled with increasing awareness about advantages of patch clamp techniques over manual methods, are fueling regional market growth. Leading global players are also focusing on expanding their presence in Asia Pacific through acquisitions and partnerships with regional life science organizations.
Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
